The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Abstract
A randomized clinical trial was conducted in women with stage III ovarian carcinoma (less than or equal to 1 cm residual lesions), using cyclophosphamide plus cisplatin (CP) with or without doxorubicin. There were 349 evaluable patients, of whom 176 received CP while 173 patients received CP plus doxorubicin (CAP). Hematologic toxicity was almost identical. There was no significant difference in progression-free interval (PFI) (median, 22.7 months and 24.6 months), frequency of negative second-look laparotomy (30.2% and 32.8%), or survival (median, 31.2 months and 38.9 months) between CP and CAP, respectively. Thus, doxorubicin in the dose schedule employed does not improve combination chemotherapy of optimal stage III ovarian carcinoma. Several other findings, independent of treatment arm, were of interest. There was a significant difference in PFI and survival by residual disease category (yes v no) and by grade of differentiation (1 v 2 + 3). In multivariate analysis, age, residual disease at entry, cell type (clear cell carcinoma), and time from surgery to initiation of chemotherapy were significant predictors of survival. There was no difference in outcome comparing those who refused second-look with those who had a second-look.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,845
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793
Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E., van Oosterom, A. T., Willemse, P. H., Heintz, A. P., van Lent, M., Trimbos, J. B., Bouma, J., & Vermorken, J. B. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1157 · Cited by 305
Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986) · Cancer · doi:10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j · Cited by 278
Self-citationRubinstein, L. V., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 267
Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin
Bruckner, H. W., Cohen, C. J., Goldberg, J. D., KABAKOW, B., Wallach, R. C., Deppe, G., Greenspan, E. M., Gusberg, S. B., & Holland, J. F. (1981) · Cancer · Cited by 111
Edmonson, J. H., Fleming, T. R., Decker, D. G., Malkasian, G. D., Jorgensen, E. O., Jefferies, J. A., Webb, M. J., & Kvols, L. K. (1979) · PubMed · Cited by 102
Cited by
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Metadata
- Authors
- Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & Mortel, R.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-04
- Volume
- 7
- Issue
- 4
- Pages
- 457-465
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1930308991
- Cited by
- 321
- References
- 12
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. https://app.cochat.ai/papers/10.1200/jco.1989.7.4.457
- The paper
- Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & Mortel, R. (1989). Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1989.7.4.457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.